Immunotherapies that block the immune checkpoint programmed cell death protein 1 (PD-1) receptor and its ligand (PD-L1) have become the standard backbone therapy in the treatment of NSCLC lacking actionable genetic alterations, improving patients’ outcomes in a range of clinical scenarios (3–5). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.